Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.57 |
| ▸ | GSK3B | P49841 | 7/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6524933 | 1.00 | PDPK1 (0.57) | PDPK1GSK3BAPPMAPTPSEN1 | |
| SCHEMBL12848482 | 0.92 | PDPK1 (0.57) | PDPK1GSK3BAPPMAPTPSEN1 | |
| SCHEMBL6522169 | 0.90 | PDPK1 (0.46) | PDPK1GSK3BAPPMAPTPSEN1 | |
| SCHEMBL6522165 | 0.90 | PDPK1 (0.46) | PDPK1GSK3BAPPMAPTPSEN1 | |
| SCHEMBL6522949 | 0.84 | GSK3B (0.67) | PDPK1GSK3BAPPMAPTLRRK2 | |
| SCHEMBL6522958 | 0.84 | GSK3B (0.67) | PDPK1GSK3BAPPMAPTLRRK2 | |
| SCHEMBL12848510 | 0.82 | PDPK1 (0.46) | PDPK1GSK3BAPPMAPTPSEN1 | |
| SCHEMBL6524884 | 0.82 | SRC (0.51) | APPMAPT | |
| SCHEMBL6524883 | 0.82 | SRC (0.51) | APPMAPT | |
| SCHEMBL12848623 | 0.82 | SRC (0.51) | APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | PDPK1 246/4885GSK3B 621/4885APP 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.